Gilead Sciences to Acquire Arcellx to Maximize Long Term Potential of Anito cel
Gilead Sciences • • business
Key Points:
- Gilead Sciences has agreed to acquire biotechnology company Arcellx for $115 per share in cash plus a contingent value right of $5 per share, valuing the deal at approximately $7.8 billion, with the transaction expected to close in Q2 2026 pending regulatory and shareholder approvals.
- The acquisition includes Arcellx’s lead product, anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy for multiple myeloma, which has shown promising clinical results and has a Biologics License Application accepted by the FDA with a PDUFA date set for December 23, 2026.
- Gilead aims to leverage anito-cel as a potential
